Elranatamab in combination with carfilzomib and dexamethasone demonstrated clinical efficacy and predictable safety signals, according to the investigators of a phase 1b MagnetisMM-20 trial in relapsed or refractory multiple myeloma.

The trial results were presented as an abstract during the American Society of Hematology Annual Meeting and Exposition by Michael H. Tomasson, MD, of the Department of Internal Medicine at the University of Iowa in Iowa City.

The trial enrolled 12 patients aged 45 to 80, each having undergone one to three prior lines of therapy. Participants received a priming dose regimen of subcutaneous elranatamab, followed by weekly doses, in combination with carfilzomib and dexamethasone. The primary endpoint was to assess dose-limiting toxicities within the first 42 days.

Results indicated that no dose-limiting toxicities were observed during this period. The most common adverse event was cytokine release syndrome, which occurred in 83.3% of patients, primarily at grade 1 or 2 severity. Notably, no instances of immune effector cell-associated neurotoxicity syndrome were reported. Efficacy outcomes showed an objective response rate of 83.3%, with 41.7% achieving a complete response. The median time to response was one month, and the median duration of response had not been reached at the time of reporting.

The investigators noted that the trial is still enrolling and the triplet regimen will be explored in a larger group of patients.

Reference

Tomasson M, Gabayan E, Ali SA. Efficacy of Elranatamab (ELRA) in Combination with Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM). Abstract 1024. Presented at the American Society of Hematology Annual Meeting and Exposition; San Diego, California.